We are just one of many organisations across the globe working to tackle cancer. By partnering with those who share our goals, we can accelerate progress and make a real difference for people affected by cancer.
We collaborate with organizations of all sizes across the UK and internationally within the non-commercial sector, including charities, government funding agencies, and research and academic institutions. We are also open to new partnerships that align with our research strategy.
Contact us to discuss partnering opportunitiesLearn more about our research strategyWe have a flexible approach to research partnerships and will work with you to find the most suitable partnering model. Our existing partnerships range from research co-funding to international alliances, novel transformative initiatives and joint workshops and conferences.
By partnering with us, you’ll benefit from our extensive expertise in research funding, review and governance. Our network includes more than 4,000 scientists, doctors and nurses and a portfolio of £399m in funding for new and ongoing research (2023/24).
Explore highlights from our latest annual report
Our strategic research partners are located in countries across the globe and range from small cancer specific charities to large multi-national funding organisations. Here are just a few examples showing the wide range of initiatives enabled through our current partnerships.
ACED is a £50m partnership with the Dana Farber Cancer Institute, The University of Manchester, the German Cancer Research Center (DKFZ), The University College London, Knight Cancer Institute at OHSU and The University of Cambridge. The Alliance unites world-leading researchers from institutions around the globe to tackle the most pressing challenges facing cancer early detection research.
Cancer Data Driven Detection is a joint initiative between the NIHR, the Engineering & Physical Sciences Research Council, Health Data Research UK and Administrative Data Research UK. The consortium aims to generate new data-driven models that significantly increase the accuracy of predicting cancer risk, enabling more precise targeting of early detection and prevention therapies.
Our Cancer Prevention Research Conference is run in partnership with the American Cancer Society. This event is building a multidisciplinary community to foster new collaborations and enable advances in future cancer prevention approaches. The next conference will be held June 3-5 in Atlanta, Georgia, USA.
The SMP2 programme is run in collaboration with the Experimental Cancer Medicines Network, the NHS, University of Birmingham Cancer Research Clinical Trials Unit and industry partners: Illumina, Astra Zeneca and Pfizer. Focussed on lung cancer, the programme links national pre-screening services through the NHS to a national cancer trial.
CRC-STARS aims to improve treatments for colorectal cancer based on a better understanding of how tumours respond and adapt to drug treatments. This £5m co-funded project with the Bowelbabe Fund, Bjorn Saven CBE and Inger Saven and the Scientific Foundation of the Spanish Association Against Cancer supports a multidisciplinary, international team of investigators.
We invest in people and partners who can help us deliver research of the highest quality.
Our research strategy shapes how we’ll discover more about how cancer develops and progresses to unlock new and better ways to prevent, detect and treat it.
If you’re interested in partnering, but are seeking corporate or commercial opportunities, explore whether our other partnering teams might be the right fit for you.
Explore our corporate partnerships
Explore commercial partnerships with Cancer Research Horizons
Stay up to date with research funding and partnership opportunities, networking events and conferences, and other research news.
We host scientific and translational conferences, workshops, webinars and other events and are always seeking new partnering opportunities.
